Oppenheimer analyst Francois Brisebois raised the firm’s price target on Praxis Precision (PRAX) to $163 from $143 and keeps an Outperform rating on the shares. The firm recently spent time with management and comes away more positive. Looking forward to updates on the upcoming quarterly call, Oppenheimer has decided to add Praxis’s U.S. Relutrigine program for Developmental Epileptic Encephalopathy to its valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX: